Thermo Fisher Scientific (TMO) Liabilities and Shareholders Equity (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $113.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 11.8% year-over-year to $113.2 billion; the trailing twelve-month figure through Jun 2026 stood at $439.8 billion (up 10.52% YoY), and the FY2025 full-year result was $110.3 billion, up 13.38% from the prior year.
• Liabilities and Shareholders Equity was little changed at $113.2 billion in Q2 2026 per TMO's latest filing, from $113.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $113.3 billion in Q1 2026 and bottomed at $90.5 billion in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $99.4 billion across 5 years, with a median of $97.9 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 40.67% in 2022, then dropped 1.42% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $97.2 billion in 2022, then grew by 1.62% to $98.7 billion in 2023, then dropped by 1.42% to $97.3 billion in 2024, then increased by 13.38% to $110.3 billion in 2025, then rose by 2.57% to $113.2 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $113.2 billion, $113.3 billion, and $110.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.